Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • hajime
    Member
    • Mar 2011
    • 14

    #1

    Problems with QC results of Illumina Body Map 2.0

    Dear all:

    I'm new in the sequencing analysis.

    Recently, I've downloaded the RNA-seq data of Illumina Body Map 2.0.
    (The accession number is GSE30611.)

    The data was applied this following processes:
    (1) All the SRA files were converted to Sanger FASTAQ.
    (2) Sanger FASTQ files without any manipulation was uploaded to Galaxy.
    (3) Fastx toolkit was used to draw the quality plot of these sequences.

    Finally, I got some strange results of quality control.
    For example, both of single-end and pair-end sequence from Brian tissue shows bad QC from the first base to 10th base nucleotide (shown in following figures). It's not a typical QC plot for Illumian sequencing.

    Single-end:

    Pair-end:


    I think there may be some problems in library-constructing step.
    Does anyone can give me any idea why I got these results?

    Thanks!

    Best,
    Yi
    Yi John Huang (PhD student)
    886-3-2118800 ext. 3731
    Graduate Institute of Biomedical Science, Chang Gung University
  • kopi-o
    Senior Member
    • Feb 2008
    • 319

    #2
    I believe the pattern of lower quality scores in the beginning is quite common in Illumina data. Overall, these quality scores are remarkably good. The median never drops below 30!

    Comment

    • hajime
      Member
      • Mar 2011
      • 14

      #3
      Originally posted by kopi-o View Post
      I believe the pattern of lower quality scores in the beginning is quite common in Illumina data. Overall, these quality scores are remarkably good. The median never drops below 30!
      Thanks for replying!

      In facts, I've never seen this kind of data before...
      The data I processed before contained lower quality at the end of sequences only...

      Therefore, I feel confused...

      Why or how does the Illumina generate the lower quality score in the beginning sequences?

      Thanks again!
      Yi John Huang (PhD student)
      886-3-2118800 ext. 3731
      Graduate Institute of Biomedical Science, Chang Gung University

      Comment

      • kopi-o
        Senior Member
        • Feb 2008
        • 319

        #4
        See this thread:

        Bridged amplification & clustering followed by sequencing by synthesis. (Genome Analyzer / HiSeq / MiSeq)

        Comment

        • hajime
          Member
          • Mar 2011
          • 14

          #5
          Excuse me, there is another question here:

          The first quantile (25%) for the first 10 bases in this data is lower than Q30 even Q20. Indeed, that means there are 25% reads contains bad q-score in the first 10 bases, doesn't it?

          Should I trim the first 10 bases that with lower quality out for all sequences at the beginning of data processing? or trim out only the sequences that contain lower q-score?
          Yi John Huang (PhD student)
          886-3-2118800 ext. 3731
          Graduate Institute of Biomedical Science, Chang Gung University

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
            by SEQadmin2




            NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
            Yesterday, 06:46 AM
          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            10-14-2026, 09:55 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 10-28-2026, 09:57 AM
          0 responses
          26 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-28-2026, 09:51 AM
          0 responses
          17 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 11:13 AM
          0 responses
          71 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 10:48 AM
          0 responses
          48 views
          0 reactions
          Last Post SEQadmin2  
          Working...